How does AVE's PS Ratio compare to its peers?

AVE is expensive based on its Price-To-Sales Ratio (18.7x) compared to the peer average (2.7x).

How does AVE's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

AVE is expensive based on its Price-To-Sales Ratio (18.7x) compared to the Australian Pharmaceuticals industry average (4.7x).

What is AVE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AVE's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of AVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate AVE's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Avecho Biotechnology (CHIA:AVE) - Stock Price, News & Analysis

AVE Stock Overview

A biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. More details

AVE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 26.6% per year over past 5 years

Does not have a meaningful market cap (A$6M)

Makes less than USD$1m in revenue (A$339K)

Highly volatile share price over the past 3 months compared to the Australian market

+ 1 more risk

Avecho Biotechnology Limited Competitors

Epsilon Healthcare

ASX:EPN

AU$7.2m

Ecofibre

ASX:EOF

AU$15.4m

Emyria

ASX:EMD

AU$14.5m

Cann Global

ASX:CGB

AU$5.4m

Price History & Performance

Summary of all time highs, changes and price drops for Avecho Biotechnology
Historical stock prices
Current Share Price	AU$0.0025
52 Week High	AU$0.005
52 Week Low	AU$0.0015
Beta	2.12
11 Month Change	25.00%
3 Month Change	-16.67%
1 Year Change	-28.57%
33 Year Change	-84.38%
5 Year Change	-37.50%
Change since IPO	-96.91%

Recent updates

Shareholder Returns

	AVE	AU Pharmaceuticals	AU Market
7D	-16.7%	-16.3%	0.9%
1Y	-28.6%	35.0%	17.7%

Return vs Industry: AVE underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.

Return vs Market: AVE underperformed the Australian Market which returned 17.2% over the past year.

Price Volatility

Is AVE's price volatile compared to industry and market?
AVE volatility
AVE Average Weekly Movement	45.4%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.3%

Stable Share Price: AVE's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: AVE's weekly volatility has increased from 34% to 45% over the past year.

About the Company

Founded	Employees	CEO	Website
1992	n/a	Paul Gavin	avecho.com.au

Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations.

Avecho Biotechnology Limited Fundamentals Summary

How do Avecho Biotechnology's earnings and revenue compare to its market cap?
AVE fundamental statistics
Market cap	AU$6.34m
Earnings (TTM)	-AU$3.48m
Revenue (TTM)	AU$339.30k

18.7x

P/S Ratio

-1.8x

P/E Ratio

Is AVE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVE income statement (TTM)
Revenue	AU$339.30k
Cost of Revenue	AU$494.03k
Gross Profit	-AU$154.73k
Other Expenses	AU$3.33m
Earnings	-AU$3.48m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0011
Gross Margin	-45.60%
Net Profit Margin	-1,026.91%
Debt/Equity Ratio	0%

How did AVE perform over the long term?

See historical performance and comparison

AVE Stock Overview

Risk Analysis

Avecho Biotechnology Limited Competitors

ASX:EPN

AU$7.2m

ASX:EOF

AU$15.4m

ASX:EMD

AU$14.5m

ASX:CGB

AU$5.4m

Price History & Performance

Recent News & Updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Recent updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)